Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is one of the most lethal tumour types world-wide. The majority of patients present late with locally advanced or metastatic disease. Therefore, despite advances in operative techniques, perioperative management and oncological treatments, the overall 5-year survival remains <5%. Determining tumoural factors that contribute towards its aggressive nature may help in identifying novel molecular biomarkers and/or therapeutic targets. MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate target gene expression and are able to act as tumour suppressors or oncogenes. MiRNAs have been extensively profiled and implicated in the initiation and progression of PDAC. Furthermore...
Background: Pancreatic ductal adenocarcinoma (PDAC), the most prevalent neoplastic lethal pancreatic...
Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy. Disease is diagnosed ...
Pancreatic cancer is a fatal cancer which is expected to exceed breast cancer as the third foremost ...
Background & Aims There has not been a broad analysis of the combined effects of altered activities...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and hi...
MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC),...
Background. Pancreatic cancer is a devastating disease; its lethality is related to rapid growth and...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
Pancreatic cancer is an aggressive disease and the fourth most lethal cancer in developed countries....
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality an...
Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
Background: Pancreatic ductal adenocarcinoma (PDAC), the most prevalent neoplastic lethal pancreatic...
Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy. Disease is diagnosed ...
Pancreatic cancer is a fatal cancer which is expected to exceed breast cancer as the third foremost ...
Background & Aims There has not been a broad analysis of the combined effects of altered activities...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with increasing incidence and hi...
MicroRNA (miRNA) expression profiles have been described in pancreatic ductal adenocarcinoma (PDAC),...
Background. Pancreatic cancer is a devastating disease; its lethality is related to rapid growth and...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
A severe lack of early diagnosis coupled with resistance to most available therapeutic options rende...
Pancreatic cancer is an aggressive disease and the fourth most lethal cancer in developed countries....
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a poor prognosis, short overall survival and...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality an...
Purpose: MicroRNAs (miRNA) have potential as diagnostic and prognostic biomarkers and as therapeutic...
Background: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PCa with 2-9% 5-year ...
Background: Pancreatic ductal adenocarcinoma (PDAC), the most prevalent neoplastic lethal pancreatic...
Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy. Disease is diagnosed ...
Pancreatic cancer is a fatal cancer which is expected to exceed breast cancer as the third foremost ...